The FDA’s office that investigates complaints and disputes between reviewers and the drug industry is currently unavailable ...

U.S. Food and Drug Administration Commissioner Martin Makary announced on Thursday a policy to limit employees of companies ...

Two former FDA leaders look at Commissioner Marty Makary’s early stumbles — and lay out a list of priorities to protect both ...

WASHINGTON — The Food and Drug Administration will remove industry representatives from advisory committees and replace them ...

Mass layoffs at the Department of Health and Human Services are continuing as the agency makes good on its intention, ...

This article examines the legal implications of AI in healthcare, focusing on liability issues and the need for clear accountability in medical AI applications.

Public records requested under the Freedom of Information Act have helped shape health policy and keep the government ...

Simulations Plus leverages AI-driven tools to revolutionize drug discovery, cut R&D costs, and capitalize on FDA regulatory ...

The question is not whether AI will transform healthcare; it’s whether regulators can keep pace with that transformation.

FDA Commissioner Martin Makary said this move would offer newer treatments for patients quicker, while also reducing the cost of research and development. Other news includes: lab models of pain ...

FRIDAY, March 21, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has launched the Chemical Contaminants Transparency Tool (CCT Tool), an online searchable database to evaluate ...

Ann Phillips, senior director of regulatory and standards at PurpleLab, joins the podcast to discuss evolving price ...